AstraZeneca and pembrolizumab lead FDA cancer approvals in early 2026
In the first half of 2026, the FDA cleared 22 new cancer treatments. AstraZeneca topped the sponsor list, and pembrolizumab became the backbone of new drug combinations. The focus is shifting to pairing proven drugs.